Arcus Biosciences [RCUS] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Arcus Biosciences Inc.

NYSE
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Arcus Biosciences Inc. wins in 8 metrics, Axsome Therapeutics Inc. wins in 9 metrics, with 0 ties. Axsome Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcus Biosciences Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) N/A -50.54 N/A
Price-to-Book Ratio 4.99 105.31 Arcus Biosciences Inc.
Debt-to-Equity Ratio 34.71 247.03 Arcus Biosciences Inc.
PEG Ratio -7.12 0.79 Axsome Therapeutics Inc.
EV/EBITDA -6.35 -57.70 Arcus Biosciences Inc.
Profit Margin (TTM) -142.92% -28.69% Axsome Therapeutics Inc.
Operating Margin (TTM) -345.45% -18.38% Axsome Therapeutics Inc.
Return on Equity -63.26% -252.12% Arcus Biosciences Inc.
Return on Assets (TTM) -21.08% -16.81% Axsome Therapeutics Inc.
Free Cash Flow (TTM) $-484.00M $-93.89M Axsome Therapeutics Inc.
1-Year Return 183.76% 122.97% Arcus Biosciences Inc.
Price-to-Sales Ratio (TTM) 12.78 14.64 Arcus Biosciences Inc.
Enterprise Value $2.39B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 9.67 14.47 Arcus Biosciences Inc.
Gross Profit Margin (TTM) N/A 93.71% N/A
Revenue per Share (TTM) $2 $13 Axsome Therapeutics Inc.
Earnings per Share (Diluted) $-3.29 $-3.69 Arcus Biosciences Inc.
Beta (Stock Volatility) 0.86 0.47 Axsome Therapeutics Inc.
Short % of Float 11.16% 6.56% Axsome Therapeutics Inc.

Arcus Biosciences Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

RCUS
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences Inc.-2.49%-0.46%-8.41%6.38%-6.91%2.45%
Axsome Therapeutics Inc.5.09%-0.45%4.37%42.32%57.95%30.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences Inc.183.76%20.61%1.16%43.98%43.98%43.98%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Arcus Biosciences Inc. vs Axsome Therapeutics Inc.

MetricRCUSAXSM
Market Information
Market Cap i$3.20B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,560,583592,425
90 Day Avg. Volume i1,285,691602,162
Last Close$23.86$233.47
52 Week Range$7.91 - $28.72$96.09 - $238.56
% from 52W High-16.92%-2.13%
All-Time High$49.10 (Nov 22, 2021)$238.56 (May 26, 2026)
% from All-Time High-51.41%-2.13%
Growth Metrics
Quarterly Revenue Growth0.27%0.65%
Quarterly Earnings Growth0.27%0.65%
Financial Health
Profit Margin (TTM) i-1.43%-0.29%
Operating Margin (TTM) i-3.45%-0.18%
Return on Equity (TTM) i-0.63%-2.52%
Debt to Equity (MRQ) i34.71247.03
Cash & Liquidity
Book Value per Share (MRQ)$5.04$1.74
Cash per Share (MRQ)$7.83$6.31
Operating Cash Flow (TTM) i$-482,000,000$-93,405,000
Levered Free Cash Flow (TTM) i$-162,250,000$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Arcus Biosciences Inc. vs Axsome Therapeutics Inc.

MetricRCUS (Apr 26, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-50.54
Forward P/E i-7.1229.85
PEG Ratio i-7.120.79
Price to Sales (TTM) i12.7814.64
Price to Book (MRQ) i4.99105.31
Market Capitalization
Market Capitalization i$3.20B$9.51B
Enterprise Value i$2.39B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i9.6714.47
Enterprise to EBITDA i-6.35-57.70
Risk & Other Metrics
Beta i0.860.47
Book Value per Share (MRQ) i$5.04$1.74

Financial Statements Comparison: Arcus Biosciences Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRCUS (2025)AXSM (2025)
Revenue/Sales i247.00M638.50M
Cost of Goods Sold iN/A47.48M
COGS % of Revenue i0.0%7.4%
Gross Profit iN/A591.02M
Gross Margin i0.0%92.6%
Research & Development i523.00M183.28M
Operating Income (EBIT) i-386.00M-169.24M
Operating Margin i-156.3%-26.5%
EBITDA i-335.00M-160.17M
EBITDA Margin i-135.6%-25.1%
Pre-Tax Income i-353.00M-183.70M
Pre-Tax Income % of Revenue i-142.9%-28.8%
Income Tax i0-530,000
Income Tax % of Revenue i0.0%-0.1%
Net Income (Profit) i-353.00M-183.17M
Profit Margin i-142.9%-28.7%

Balance Sheet & Liquidity Metrics

MetricRCUS (2025)AXSM (2025)
Cash & Equivalents i222.00M322.93M
Total Current Assets i1.01B588.99M
Total Current Assets % of Revenue i407.7%92.2%
Total Current Liabilities i231.00M378.84M
Total Current Liabilities % of Revenue i93.5%59.3%
Long-Term Debt i99.00M145.13M
Long-Term Debt % of Revenue i40.1%22.7%
Total Shareholders Equity i631.00M88.30M
Retained Earnings i-1.49B-1.31B
Retained Earnings % of Revenue i-601.2%-204.5%
Property, Plant & Equipment i28.00M562,000

Cash Flow Statement Comparison

MetricRCUS (2025)AXSM (2025)
Operating Cash Flow i-469.00M-185.86M
Operating Cash Flow % of Revenue i-189.9%-29.1%
Capital Expenditures i-2.00M-480,000
Free Cash Flow i-484.00M-93.89M
FCF Margin i-196.0%-14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricRCUSAXSM
Shares Short i9.88M2.83M
Short Ratio i7.594.92
Short % of Float i11.16%6.56%
Shares Outstanding i125.30M50.88M
Float Shares i88.65M43.24M
% Held by Insiders i29.17%15.47%
% Held by Institutions i74.41%76.52%
% Held by Public i-3.58%8.01%

Dividend Analysis & Yield Comparison: Arcus Biosciences Inc. vs Axsome Therapeutics Inc.

MetricRCUSAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A